Efficacy and Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.

Séverine VermeireSilvio DaneseWilliam J SandbornStefan SchreiberStephen HanauerGeert D'HaensPeter NagyManoj ThakurCaleb BlissFabio CataldiMartina GoetschKenneth J GorelickWalter Reinisch

Published in: Journal of Crohn's & colitis (2023)

Ontamalimab 75 mg was effective with no safety concerns as induction and maintenance therapy for patients with moderate-to-severe ulcerative colitis.

Keyphrases

ulcerative colitis
cell adhesion

high intensity

early onset

drug induced